Abstract
Highly undifferentiated glial tumors do not express somatostatin receptors (SSR) in contrast to low-grade astrocytomas which contain SSR. To differentiate a malignant glioma from a low-grade astrocytoma and to distinguish an SSR-positive intra-axial brain tumor from an SSR negative one, 111In-pentetreotide brain SPECT was prospectively undertaken. Methods: Eight patients with intra-axial brain tumors (three glioblastoma multiforme, one low-grade astrocytoma, one lymphoma, one medulloblastoma, one neurocytoma and one metastatic tumor) were studied. Thallium-201 and 111In- pentetreotide brain SPECT were performed with a 3- to 4-day interval before surgery. The SPECT findings were compared with those of Gd-enhanced MRI. Results: Increased uptake of 111In-pentetreotide was observed in all of the patients with glioblastoma multiforme (Grade +++ in two and Grade + in one) despite lack of SSR. Low-grade astrocytoma exhibited minimal uptake of 111In-pentetreotide (Grade +). Remaining tumors had intense uptake of 111In-pentetreotide. Thallium-201 SPECT showed similar findings to those of 111In-pentetreotide scintigraphy except in two patients with glioblastoma multiforme: One with 201Tl negative scan showed increased uptake of 111In-pentetreotide and the other showed increased thallium uptake but minimal uptake of 111In-pentetreotide. The uptake pattern of both 201Tl and 111In-pentetreotide appeared to correlate with Gd- enhanced MRI. Conclusion: Indium-111-pentetreotide scintigraphy is sensitive in the detection of intra-axial brain tumors; however, it has no role in assessing the tumor grading and in the definition of the receptor profile.
| Original language | English |
|---|---|
| Pages (from-to) | 537-541 |
| Number of pages | 5 |
| Journal | Journal of Nuclear Medicine |
| Volume | 36 |
| Issue number | 4 |
| Publication status | Published - 1995 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
Cite this
}
Indium-111-pentetreotide imaging in intra-axial brain tumors : Comparison with thallium-201 SPECT and MRI. / Jong Doo Lee, Doo Lee; Dong Ik Kim, Ik Kim; Jong Tae Lee, Tae Lee; Jin Woo Chang, Woo Chang; Chang Yun Park, Yun Park.
In: Journal of Nuclear Medicine, Vol. 36, No. 4, 01.01.1995, p. 537-541.Research output: Contribution to journal › Article
TY - JOUR
T1 - Indium-111-pentetreotide imaging in intra-axial brain tumors
T2 - Comparison with thallium-201 SPECT and MRI
AU - Jong Doo Lee, Doo Lee
AU - Dong Ik Kim, Ik Kim
AU - Jong Tae Lee, Tae Lee
AU - Jin Woo Chang, Woo Chang
AU - Chang Yun Park, Yun Park
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Highly undifferentiated glial tumors do not express somatostatin receptors (SSR) in contrast to low-grade astrocytomas which contain SSR. To differentiate a malignant glioma from a low-grade astrocytoma and to distinguish an SSR-positive intra-axial brain tumor from an SSR negative one, 111In-pentetreotide brain SPECT was prospectively undertaken. Methods: Eight patients with intra-axial brain tumors (three glioblastoma multiforme, one low-grade astrocytoma, one lymphoma, one medulloblastoma, one neurocytoma and one metastatic tumor) were studied. Thallium-201 and 111In- pentetreotide brain SPECT were performed with a 3- to 4-day interval before surgery. The SPECT findings were compared with those of Gd-enhanced MRI. Results: Increased uptake of 111In-pentetreotide was observed in all of the patients with glioblastoma multiforme (Grade +++ in two and Grade + in one) despite lack of SSR. Low-grade astrocytoma exhibited minimal uptake of 111In-pentetreotide (Grade +). Remaining tumors had intense uptake of 111In-pentetreotide. Thallium-201 SPECT showed similar findings to those of 111In-pentetreotide scintigraphy except in two patients with glioblastoma multiforme: One with 201Tl negative scan showed increased uptake of 111In-pentetreotide and the other showed increased thallium uptake but minimal uptake of 111In-pentetreotide. The uptake pattern of both 201Tl and 111In-pentetreotide appeared to correlate with Gd- enhanced MRI. Conclusion: Indium-111-pentetreotide scintigraphy is sensitive in the detection of intra-axial brain tumors; however, it has no role in assessing the tumor grading and in the definition of the receptor profile.
AB - Highly undifferentiated glial tumors do not express somatostatin receptors (SSR) in contrast to low-grade astrocytomas which contain SSR. To differentiate a malignant glioma from a low-grade astrocytoma and to distinguish an SSR-positive intra-axial brain tumor from an SSR negative one, 111In-pentetreotide brain SPECT was prospectively undertaken. Methods: Eight patients with intra-axial brain tumors (three glioblastoma multiforme, one low-grade astrocytoma, one lymphoma, one medulloblastoma, one neurocytoma and one metastatic tumor) were studied. Thallium-201 and 111In- pentetreotide brain SPECT were performed with a 3- to 4-day interval before surgery. The SPECT findings were compared with those of Gd-enhanced MRI. Results: Increased uptake of 111In-pentetreotide was observed in all of the patients with glioblastoma multiforme (Grade +++ in two and Grade + in one) despite lack of SSR. Low-grade astrocytoma exhibited minimal uptake of 111In-pentetreotide (Grade +). Remaining tumors had intense uptake of 111In-pentetreotide. Thallium-201 SPECT showed similar findings to those of 111In-pentetreotide scintigraphy except in two patients with glioblastoma multiforme: One with 201Tl negative scan showed increased uptake of 111In-pentetreotide and the other showed increased thallium uptake but minimal uptake of 111In-pentetreotide. The uptake pattern of both 201Tl and 111In-pentetreotide appeared to correlate with Gd- enhanced MRI. Conclusion: Indium-111-pentetreotide scintigraphy is sensitive in the detection of intra-axial brain tumors; however, it has no role in assessing the tumor grading and in the definition of the receptor profile.
UR - http://www.scopus.com/inward/record.url?scp=0028965919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028965919&partnerID=8YFLogxK
M3 - Article
C2 - 7699438
AN - SCOPUS:0028965919
VL - 36
SP - 537
EP - 541
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 4
ER -